原料药是制药产业链的起点，"原料药好，药才好"，好品质的核心一定是对源头的把控。海正药业多年来一直坚守原料药的根基。在生产方面，海正药 业国际化标准的生产基地重点分布在台州、富阳、南通，目前产线布局完整，具有发酵17000立方、合成2300立方的生产能力。 "重回国内第一梯队"是海正药业（600267）十五五战略规划的目标。构建以人用药为主、以动物药和医美大健康为两翼的一"主"两"翼"多元发展格局， 是未来五年海正药业为发展制定的明确路径。 来到位于杭州富阳的产业园区，一座被绿意环抱的产业群落就是海正药业在2002年布局的原料药、医药制剂生产基地。如今，当初的药用植物种植基地 已经发展为占地1500余亩的生物医药产业园，业务版图涵盖高端生物技术药物、注射和口服制剂、出口原料药、兽用原料药四大领域。 守牢原料药好品质 海正药业是中国原料药出海最早的企业之一，早在1992年便将产品打入美国市场，至今原料药产品出口至70多个国家和地区，广泛覆盖医药及医疗领 域，拥有海外客户400余家（含全球十大药企）。 在近70年的风雨洗礼中，这家老牌药企已经逐渐发展成为集研产销全价值链、原料药与制剂垂直一体化的全球化制药企业。目 ...

Group 1 - The company signed an exclusive agreement with Pfizer for the global development, production, and commercialization rights of its PD-1/VEGF bispecific antibody SSGJ-707, excluding mainland China, with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [1] - The agreement also includes a tiered sales revenue sharing based on product sales in the licensed regions, and Pfizer will purchase $100 million worth of common stock in the company upon the agreement's effective date [1] - The company maintains its profit forecast, expecting net profits of 2.328 billion, 2.612 billion, and 2.938 billion yuan for 2025-2027, with corresponding EPS of 0.97, 1.09, and 1.23 yuan per share, resulting in a current PE of 9.3, 8.3, and 7.4 times [1] Group 2 - SSGJ-707 has shown excellent ORR and DCR in the treatment of NSCLC patients, indicating its best-in-class potential, and has received breakthrough therapy designation from the National Medical Products Administration for first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC [2] - The company is advancing clinical research for SSGJ-707 in other areas, including colorectal cancer and gynecological tumors, and has received FDA IND approval [2] - The company’s existing products, such as Tebentafusp, are expected to see growth due to successful negotiations for zero price reduction in 2024 and the addition of new indications, contributing to cash flow [2]

相关研究报告 医药生物/生物制品 三生制药（01530.HK） 2025 年 05 月 22 日 投资评级：买入（维持） | 日期 | 2025/5/21 | | --- | --- | | 当前股价(港元) | 20.850 | | 一年最高最低(港元) | 22.000/5.470 | | 总市值(亿港元) | 500.10 | | 流通市值(亿港元) | 500.10 | | 总股本(亿股) | 23.99 | | 流通港股(亿股) | 23.99 | | 近 3 个月换手率(%) | 134.69 | 股价走势图 数据来源：聚源 -80% 0% 80% 160% 240% 320% 2024-05 2024-09 2025-01 三生制药 恒生指数 《核心品种持续发力，多款创新药进 入收获期—港股公司首次覆盖报告》 -2025.3.27 与辉瑞就 SSGJ-707 达成授权，创新价值弹性兑现 ——港股公司信息更新报告 | 余汝意（分析师） | 余克清（分析师） | 刘艺（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | yukeqing@kysec.cn | ...

三生制药（01530.HK） 2025 年 05 月 22 日 投资评级：买入（维持） 医药生物/生物制品 | 日期 | 2025/5/21 | | --- | --- | | 当前股价(港元) | 20.850 | | 一年最高最低(港元) | 22.000/5.470 | | 总市值(亿港元) | 500.10 | | 流通市值(亿港元) | 500.10 | | 总股本(亿股) | 23.99 | | 流通港股(亿股) | 23.99 | | 近 3 个月换手率(%) | 134.69 | 股价走势图 数据来源：聚源 -80% 0% 80% 160% 240% 320% 2024-05 2024-09 2025-01 三生制药 恒生指数 相关研究报告 《核心品种持续发力，多款创新药进 入收获期—港股公司首次覆盖报告》 -2025.3.27 与辉瑞就 SSGJ-707 达成授权，创新价值弹性兑现 ——港股公司信息更新报告 | 余汝意（分析师） | 余克清（分析师） | 刘艺（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | yukeqing@kysec.cn | ...

龙虎榜机构热股 今天机构龙虎榜上榜27只个股，净买入16只，净卖出11只。当日机构买入最多的个股前三位是：大千生态（1.06亿）、一品红（9696万）、舒泰神（6495 万）。 | 上榜热股 | 实时涨跌幅♀ 买/卖家数↕ | | | --- | --- | --- | | 大千生态 | | | | 603955.SS | +5.58% | 1/1 | | 3日 | | | | 品紅 | | | | 300723.SZ | +6.46% | 3/0 | | 3日 | | | | 舒泰神 | 120 02% | 2/1 | | 비 색 | +20.02% | | --- | --- | | 300204.SZ | | | 舒泰神 | | --- | 龙虎榜显示，3家机构净买入6495万。 公司发布的G垣准固态电池获主流车企认可 领湃科技 个股龙虎榜 公司已经完成了NCM811电池化学体系研发，固态电解质及固态电池、干法电极及其制备技术的基础试验，相关专利正在申请或已获得授权 催化上，昨日金龙羽微信公众号宣布，成功与客户签订无人机用高能量密度固态电芯采购订单，该订单所采购的电芯为EC01系列超能固态电芯，其能量密 ...

【机构龙虎榜解读】PEEK材料+氟化工+业绩增长,锚定高 性能轻量化材料需求,已布局有5000吨PEEK核心中间体产 能,3万吨电子级氢氟酸正处于试生产阶段,这家公司获净 si 电报解读 2025.05.19 18:17 星期一 一、盘面向达 市场全天震荡调整,三大指数涨跌不一。大小指数走势分化,微盘股指数涨超2%再创新高。沪深两市全天成交额1.09万亿,较 上个交易日缩量30.7亿。盘面上,市场热点较为杂乱,个股涨多跌少,全市场超3500只个股上涨,逾百股涨超8%。高位股继续 获资金追捧,中毅达等多股涨停。从板块来看,并购盘组及ST股集体大涨,光智科技等多股涨停。港口航运股再度走强,南京 港等涨停。大消费股展开反弹,食品、美容、宠物等方向走强,巴比食品等涨停。下跌方面,机器人概念股迎来调整,龙溪股份 等多股跌超5%。板块方面，港口、ST板块、并购重组、食品等板块涨幅居前，人形机器人、小金属、白酒、保险等板块跌幅居 削。 二、机构动向 据2025年4月3日机构调研,公司预计2025年将有7项重要临床数据读出,包括608项目强直性脊柱炎川期、611项目青少年中重度 AD II期等，其中613项目急性痛风性关节炎 ...

Core Viewpoint - The company is preparing for its 2024 annual general meeting, outlining the procedures and agenda for the meeting, including various proposals for shareholder approval [1][2][3]. Meeting Procedures - The meeting will ensure the presence of relevant stakeholders, including shareholders, directors, supervisors, and invited guests, while excluding unrelated personnel [1][2]. - Shareholders must register and present necessary documentation to participate in the voting process, with late arrivals not permitted to vote [2][3]. - The meeting will follow a predetermined agenda for discussing and voting on proposals [2][3]. Proposals for Approval - Proposal 1: The board's work report for 2024 has been prepared and submitted for shareholder review [5]. - Proposal 2: The financial settlement report for 2024 has been created and is ready for approval [5]. - Proposal 3: The financial budget report for 2025 has been prepared for shareholder consideration [6]. - Proposal 4: The annual report for 2024 is submitted for approval [6]. - Proposal 5: The reappointment of Ernst & Young Hua Ming as the auditing firm for 2025 is proposed [7]. - Proposal 6: A profit distribution plan for 2024 is proposed, with a cash dividend of RMB 0.90 per share [8][9]. - Proposal 7: The remuneration plan for directors in 2025 is outlined, with independent directors receiving RMB 100,000 annually [10]. - Proposal 8: The execution of related party transactions for 2024 and projections for 2025 are presented, ensuring compliance with regulations and fair pricing [11][21]. Financial Performance - The company reported a net profit of RMB 704.58 million for 2024, with an unallocated profit of RMB 2.28 billion as of December 31, 2024 [25]. - The total revenue for 2024 was RMB 1.19 billion, reflecting a stable growth trajectory [25]. - The company’s operating costs increased to RMB 304.34 million, a rise of 35.80% compared to the previous year, primarily due to increased sales volumes [25]. Governance and Compliance - The board of directors has adhered to legal requirements and company regulations in conducting meetings and decision-making processes [27][28]. - The company has established a robust internal control system to enhance governance and risk management [31].

Core Insights - In 2024, the company reported a revenue increase of 17.70% to 1.194 billion yuan and a net profit surge of 139.15% to 705 million yuan, indicating strong financial performance despite underlying challenges [1] - The company faces significant pressure on its core product due to expanded centralized procurement and shrinking market share, with a projected net profit drop of 57.42% in 2025 attributed to profit margin compression from procurement [2] - The company's strategy of divesting non-core businesses has led to a concentration in the autoimmune sector, raising concerns about pipeline risk and growth sustainability, as only three products currently support its performance [3] - The company's R&D investment remains insufficient compared to peers, with a reliance on early-stage projects from related parties potentially posing governance risks [4] - The company's transformation reflects broader challenges faced by Chinese innovative pharmaceutical companies, emphasizing the need for sustainable growth without relying on non-recurring income [5] Financial Performance - Revenue for 2024 reached 1.194 billion yuan, a 17.70% year-on-year increase [1] - Net profit for 2024 was 705 million yuan, a 139.15% increase compared to the previous year [1] - Operating cash flow for 2024 decreased by 32.48% to 281 million yuan, indicating cash flow concerns [2] Market Challenges - The core product, Yisaipu, has seen its market share decline from 40.14% in 2016 to 27.00% in 2022 due to price reductions from centralized procurement [2] - The company anticipates a significant profit drop in 2025 due to ongoing pricing pressures and increased competition from new drug entrants [2] Strategic Focus - The company has divested from oncology and ophthalmology pipelines to concentrate on the autoimmune sector, but this has led to a narrow product focus [3] - The future growth potential in the autoimmune market is promising, with projections estimating a market size of $19.9 billion by 2030, but the company faces challenges in overcoming competition and achieving successful new drug launches [3] R&D and Governance - The company has not disclosed specific R&D expenses for 2024, but acknowledges rising costs due to rapid project advancement [4] - Compared to peers, the company's R&D expense ratio is low, raising concerns about its innovation capacity [4] - Increased dependency on related party transactions may lead to governance issues and affect investor confidence [4]

Core Viewpoint - Sanofi's strategic shift towards focusing on the autoimmune sector has led to significant revenue and profit growth, despite challenges in the competitive landscape and pricing pressures from centralized procurement policies [1][4][7]. Financial Performance - In 2024, Sanofi achieved revenue of 1.194 billion yuan, a year-on-year increase of 17.70%, and a net profit attributable to shareholders of 705 million yuan, up 139.15% [1]. - The company reported a non-recurring net profit of 246 million yuan, reflecting an 18.99% increase year-on-year [1]. - Cash flow from operating activities showed a net inflow of 281 million yuan, a decrease of 32.48% compared to the previous year [2]. Product Portfolio and Market Position - Sanofi currently has three therapeutic antibody drugs on the market, with Yisaipu being the core product, alongside Jianipai and Saiputing [3]. - The market share of Yisaipu has declined from 40.14% in 2016 to 27.00% in 2022 due to increased competition [3]. - The company has faced pricing pressures due to the expansion of centralized procurement policies, with Yisaipu's average price decreasing as it entered over 20 provincial procurement programs in 2024 [3][4]. Strategic Focus and Business Model - Sanofi has divested its oncology pipeline to concentrate on the autoimmune sector, which is seen as a strategic move to enhance its core competencies and improve financial performance [5][6][7]. - The company has signed multiple agreements to transfer oncology and ophthalmology projects to its affiliate, Shenyang Sanofi, to reduce R&D costs and focus on autoimmune drug development [6][7]. - The autoimmune disease market is projected to reach $6.1 billion by 2025, with a compound annual growth rate (CAGR) of over 20% [9]. Industry Trends and Opportunities - The autoimmune disease market is characterized by a growing patient population and a significant unmet clinical need, with only about 30 treatment options currently available globally [8][9]. - The market for biological agents in autoimmune diseases is expected to grow from 12 billion dollars in 2022 to 138 billion dollars by 2030, indicating a robust opportunity for innovation and development in this sector [9].